Patents by Inventor Patrick Gianpietro Spinazze

Patrick Gianpietro Spinazze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220017496
    Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 20, 2022
    Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
  • Patent number: 11124500
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
  • Publication number: 20200392118
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 17, 2020
    Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
  • Patent number: 9469632
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Kevin Matthew Gardinier, Douglas Linn Gernert, Patric James Hahn, Sean Patrick Hollinshead, Albert Khilevich, Daniel Ray Mayhugh, Paul Leslie Ornstein, Warren Jaye Porter, Jon Kevin Reel, Jeffrey Michael Schkeryantz, Patrick Gianpietro Spinazze, Freddie Craig Stevens, Jeffrey Michael Witkin
  • Publication number: 20150344468
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Application
    Filed: May 21, 2015
    Publication date: December 3, 2015
    Inventors: Kevin Matthew GARDINIER, Douglas Linn GERNERT, Patric James HAHN, Sean Patrick HOLLINSHEAD, Albert KHILEVICH, Daniel Ray MAYHUGH, Paul Leslie ORNSTEIN, Warren Jaye PORTER, Jon Kevin REEL, Jeffrey Michael SCHKERYANTZ, Patrick Gianpietro SPINAZZE, Freddie Craig STEVENS, Jeffrey Michael WITKIN
  • Patent number: 8202873
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: June 19, 2012
    Assignee: Eli Lilly and Company
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • Patent number: 8101764
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu, Patrick Gianpietro Spinazze
  • Publication number: 20100120785
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)? or N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R14 are as defined herein.
    Type: Application
    Filed: May 7, 2008
    Publication date: May 13, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • Publication number: 20100016350
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Application
    Filed: June 8, 2007
    Publication date: January 21, 2010
    Inventors: Albert Kudzovi Amegadzie, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianlaing Lu, Patrick Gianpietro Spinazze
  • Patent number: 7384934
    Abstract: Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or —CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, NO2, CN, COR4, C(O)OR4, CONR5R6, NR5R6, SO2NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyly is unsubstituted or substituted with a phenyl; R4 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: June 10, 2008
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Yvan LeHuerou, Fionna Mitchell Martin, Marta Maria Pineiro-Nunez, Vincent Patrick Rocco, Kevin Michael Ruley, John Mehnert Schaus, Patrick Gianpietro Spinazze, David Edward Tupper
  • Patent number: 7208505
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 24, 2007
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Rushad Eruch Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Patent number: 7144898
    Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: December 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Marvin Martin Hansen, John Xiaoqiang He, Nicholas Allan Honigschmidt, Daniel James Koch, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
  • Patent number: 7087635
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz, Theo Schotten, Gerd Reuhter
  • Patent number: 6911463
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Patent number: 6844344
    Abstract: The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: January 18, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
  • Patent number: 6835733
    Abstract: The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: December 28, 2004
    Assignee: Eli Lilly and Company
    Inventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
  • Publication number: 20040242668
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Patent number: 6784180
    Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: August 31, 2004
    Assignee: Eli Lilly and Company
    Inventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
  • Publication number: 20040006229
    Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
    Type: Application
    Filed: September 30, 2002
    Publication date: January 8, 2004
    Inventors: Marvin Martin Hansen, John Xiaoqiang He, Nicholas Allan Honigschmidt, Daniel James Koch, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
  • Publication number: 20030232833
    Abstract: The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
    Type: Application
    Filed: October 8, 2002
    Publication date: December 18, 2003
    Inventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi